Tweet
Hello all. Can anyone offer insight into the pros and cons of placing index barcodes at the 5' versus the 3' end of the read?
-
-
5' of the read allows you to run multiplexed samples without doing the index read. I liked to do this on the GAII to avoid using the Paired-End module for SR multiplexing. Con is that the bases need to be balanced or you can throw off the cluster calling algorithms. Use cycle 5+ to avoid this type of problem.
3' end of read must mean the standard Illumina indexing method using a second priming and read to hit the index. That method works fine, extra reagents are in the SBS kits to allow for 7 cycles for the index read. Illumina only has 12-indexes for DNA and RNA out so far, so that would be a con. On the HiSeq this indexing read is easy to set up, I avoided it on the GAII. -
Thanks for the info!Comment
-
Bioo has 48 barcodes using the 3' method. The kit works well.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment